Received Feb 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
Possible late second dose; This non-serious case was reported by a other health professional via call center representative and described the occurrence of extra dose administered in a 69-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose of Shingrix vaccine on 02-FEB-2024 with batch number J294K). On 23-JAN-2025, the patient received the 2nd dose of Shingrix. On 23-JAN-2025, 356 days after receiving Shingrix, the patient experienced extra dose administered (Verbatim: Possible late second dose). The outcome of the extra dose administered was unknown. Additional Information: GSK Receipt Date: 23-JAN-2025 The reporter reported that the possible administration of a 3rd dose of Shingrix to a patient who does not remember receiving a 2nd dose of Shingrix, which led to extra dose administered. The manager stated that they needed data about the indication from GlaxoSmithKline. After the call, they stated that if the second dose had not been given, this would possibly qualify as a late second dose. As neither the patient nor the healthcare professional can clarify if the dose was given or not, a possible.